Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

@article{Sun2014ReversibleAA,
  title={Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma},
  author={Chong Sun and Liqin Wang and Sidong Huang and Guus Heynen and Anirudh Prahallad and Caroline Robert and John H. Haanen and Christian Blank and Jelle Wesseling and Stefan M. Willems and Davide Zecchin and Sebastijan Hobor and Prashanth Kumar Bajpe and C. Lieftink and Christina Mateus and St{\'e}phan Vagner and Wipawadee Grernrum and Ingrid Hofland and Andreas Schlicker and L. F. A. Wessels and Roderick Leonardus Beijersbergen and Alberto Bardelli and Federica Di Nicolantonio and A. M. M. Eggermont and Ren{\'e} Bernards},
  journal={Nature},
  year={2014},
  volume={508},
  pages={118-122}
}
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably. In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR). Here we show that 6 out of 16 melanoma tumours analysed acquired EGFR expression after the development of resistance to BRAF or MEK inhibitors. Using a… CONTINUE READING
Highly Influential
This paper has highly influenced 17 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 39 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
200 Citations
26 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 200 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 26 references

re-activation ofMAPKsignaling contributes to insensitivity ofBRAFmutantcolorectal cancers toRAF inhibitionwith vemurafenib

  • Corcoran, R.B.et al.EGFR-mediated
  • Cancer Discov
  • 2012

Similar Papers

Loading similar papers…